Post by icemandios on Mar 14, 2018 18:39:02 GMT
On March 9, 2018, Novus Therapeutics, Inc. (the “Company”) announced that it had concluded its offering of common stock under its “at-the-market” offering facility described in that certain prospectus dated August 21, 2017 and filed under Rule 424(b)(5) (File No. 333-207359) (the “Prospectus”). Accordingly, no further sales of Common Stock will be made pursuant to the Prospectus. The Company raised aggregate gross offering proceeds of approximately $8.5 million and issued a total of 2,463,966 shares of common stock under the Prospectus since September 30, 2017. As of the date hereof, and giving effect to the shares sold under the Prospectus, the Company has a total of 9,407,024 shares of common stock issued and outstanding.
[Note: I posted this in the wrong place originally]
[Note: I posted this in the wrong place originally]